0	14	Constitutively	constitutively	RB
15	24	activated	activate	VBN
25	33	Jak-STAT	jak-stat	JJ
34	41	pathway	pathway	NN
42	44	in	in	IN
45	46	T	t	NN
47	52	cells	cell	NNS
53	64	transformed	transform	VBN
65	69	with	with	IN
70	76	HTLV-I	HTLV-I	NNP
76	77	.	.	.

79	84	Human	human	JJ
85	86	T	t	NN
87	91	cell	cell	NN
92	104	lymphotropic	lymphotropic	JJ
105	110	virus	virus	NN
111	112	I	i	CD
113	114	(	(	(
114	120	HTLV-I	HTLV-I	NNP
120	121	)	)	)
122	124	is	be	VBZ
125	128	the	the	DT
129	140	etiological	etiological	JJ
141	146	agent	agent	NN
147	150	for	for	IN
151	156	adult	adult	JJ
157	158	T	t	NN
159	163	cell	cell	NN
164	172	leukemia	leukemia	NN
173	176	and	and	CC
177	185	tropical	tropical	JJ
186	193	spastic	spastic	JJ
194	205	paraparesis	paraparesis	NN
206	207	(	(	(
207	211	also	also	RB
212	218	termed	term	VBN
219	236	HTLV-I-associated	htlv-i-associated	JJ
237	247	myelopathy	myelopathy	NN
247	248	)	)	)
248	249	.	.	.

250	265	HTLV-I-infected	htlv-i-infected	JJ
266	276	peripheral	peripheral	JJ
277	282	blood	blood	NN
283	284	T	t	NN
285	290	cells	cell	NNS
291	298	exhibit	exhibit	VBP
299	301	an	an	DT
302	309	initial	initial	JJ
310	315	phase	phase	NN
316	318	of	of	IN
319	332	interleukin-2	interleukin-2	NN
333	334	(	(	(
334	349	IL-2)-dependent	il-2)-dependent	JJ
350	356	growth	growth	NN
356	357	;	;	:
358	362	over	over	IN
363	367	time	time	NN
367	368	,	,	,
369	371	by	by	IN
372	374	an	an	DT
375	382	unknown	unknown	JJ
383	392	mechanism	mechanism	NN
392	393	,	,	,
394	397	the	the	DT
398	403	cells	cell	NNS
404	410	become	become	VBP
411	427	IL-2-independent	il-2-independent	JJ
427	428	.	.	.

429	436	Whereas	whereas	IN
437	440	the	the	DT
441	444	Jak	Jak	NNP
445	452	kinases	kinase	NNS
453	457	Jak1	Jak1	NNP
458	461	and	and	CC
462	466	Jak3	Jak3	NNP
467	470	and	and	CC
471	474	the	the	DT
475	481	signal	signal	NN
482	492	transducer	transducer	NN
493	496	and	and	CC
497	506	activator	activator	NN
507	509	of	of	IN
510	523	transcription	transcription	NN
524	532	proteins	protein	NNS
533	538	Stat3	Stat3	NNP
539	542	and	and	CC
543	548	Stat5	Stat5	NNP
549	552	are	be	VBP
553	562	activated	activate	VBN
563	565	in	in	IN
566	572	normal	normal	JJ
573	574	T	t	NN
575	580	cells	cell	NNS
581	583	in	in	IN
584	592	response	response	NN
593	595	to	to	TO
596	600	IL-2	il-2	NN
600	601	,	,	,
602	606	this	this	DT
607	616	signaling	signaling	NN
617	624	pathway	pathway	NN
625	628	was	be	VBD
629	643	constitutively	constitutively	RB
644	653	activated	activate	VBN
654	656	in	in	IN
657	675	HTLV-I-transformed	htlv-i-transformed	JJ
676	681	cells	cell	NNS
681	682	.	.	.

683	685	In	in	IN
686	701	HTLV-I-infected	htlv-i-infected	JJ
702	706	cord	cord	NN
707	712	blood	blood	NN
713	724	lymphocytes	lymphocyte	NNS
724	725	,	,	,
726	729	the	the	DT
730	740	transition	transition	NN
741	745	from	from	IN
746	760	IL-2-dependent	il-2-dependent	JJ
761	763	to	to	TO
764	780	IL-2-independent	il-2-independent	JJ
781	787	growth	growth	NN
788	798	correlated	correlate	VBD
799	803	with	with	IN
804	807	the	the	DT
808	819	acquisition	acquisition	NN
820	822	of	of	IN
823	824	a	a	DT
825	839	constitutively	constitutively	RB
840	849	activated	activate	VBN
850	858	Jak-STAT	jak-stat	JJ
859	866	pathway	pathway	NN
866	867	,	,	,
868	873	which	which	WDT
874	882	suggests	suggest	VBZ
883	887	that	that	IN
888	892	this	this	DT
893	900	pathway	pathway	NN
901	913	participates	participate	VBZ
914	916	in	in	IN
917	932	HTLV-I-mediated	htlv-i-mediated	JJ
933	934	T	t	NN
935	939	cell	cell	NN
940	954	transformation	transformation	NN
954	955	.	.	.